- Home
- ARMP vs IMRX Comparison
ARMP vs IMRX Comparison
Compare ARMP & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- IMRX
- Stock Information
- Founded
- ARMP N/A
- IMRX 2008
- Country
- ARMP United States
- IMRX United States
- Employees
- ARMP N/A
- IMRX N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- IMRX Health Care
- Exchange
- ARMP Nasdaq
- IMRX Nasdaq
- Market Cap
- ARMP 80.0M
- IMRX 73.2M
- IPO Year
- ARMP N/A
- IMRX 2021
- Fundamental
- Price
- ARMP $1.98
- IMRX $1.69
- Analyst Decision
- ARMP Strong Buy
- IMRX Buy
- Analyst Count
- ARMP 1
- IMRX 7
- Target Price
- ARMP $7.00
- IMRX $12.80
- AVG Volume (30 Days)
- ARMP 9.2K
- IMRX 801.9K
- Earning Date
- ARMP 11-13-2024
- IMRX 11-13-2024
- Dividend Yield
- ARMP N/A
- IMRX N/A
- EPS Growth
- ARMP N/A
- IMRX N/A
- EPS
- ARMP N/A
- IMRX N/A
- Revenue
- ARMP $5,467,000.00
- IMRX N/A
- Revenue This Year
- ARMP N/A
- IMRX N/A
- Revenue Next Year
- ARMP $83.33
- IMRX N/A
- P/E Ratio
- ARMP N/A
- IMRX N/A
- Revenue Growth
- ARMP 34.92
- IMRX N/A
- 52 Week Low
- ARMP $1.97
- IMRX $1.00
- 52 Week High
- ARMP $4.48
- IMRX $8.07
- Technical
- Relative Strength Index (RSI)
- ARMP 38.26
- IMRX 37.40
- Support Level
- ARMP $1.97
- IMRX $1.52
- Resistance Level
- ARMP $2.30
- IMRX $1.93
- Average True Range (ATR)
- ARMP 0.11
- IMRX 0.19
- MACD
- ARMP -0.02
- IMRX -0.05
- Stochastic Oscillator
- ARMP 7.50
- IMRX 21.95
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.